Stock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations

Stock Track

2025/05/02

Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.

GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.

Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1118468982"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118468982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118468982?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118468982","market":"us","top_or_hot":-1,"title":"Stock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations","media":"Stock Track","content":"<p>Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.</p>\n\n<p>GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.</p>\n\n<p>Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-05-02 22:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.</p>\n\n<p>GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.</p>\n\n<p>Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"","article_id":"1118468982","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118468982","pubTimestamp":1746195267,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GeneDx Holdings  are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings"},"translate_title":"股票轨迹GeneDx Holdings(WGS)因2025年第一季度盈利超出预期而飙升5.58%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1},"content_text":"Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.\nGeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.\nInvestors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}